Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Psoriatic arthritis Stories

2012-11-12 08:29:02

THOUSAND OAKS, Calif. and NEW YORK, Nov. 12, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) today announced that results from several Enbrel(®) (etanercept) studies will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) 2012 Annual Meeting in Washington, D.C. from Nov. 10-14, 2012. "Moderate to severe rheumatoid arthritis (RA) places a significant burden on patients, and we are pleased that ENBREL...

2012-11-12 08:27:42

WASHINGTON, Nov. 12, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today new findings from PSUMMIT II, a Phase 3 investigational study that showed patients with active psoriatic arthritis, including those previously treated with one to five tumor necrosis factor (TNF) inhibitors, receiving the interleukin (IL)-12/23 inhibitor STELARA(®) (ustekinumab) demonstrated significant improvements in signs and symptoms of the disease. Significantly more patients...

2012-11-02 07:27:32

NEW BRUNSWICK, N.J., Nov. 2, 2012 /PRNewswire/ -- Janssen and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, November 10, at approximately 5:00 p.m., Eastern Time, to coincide with the American College of Rheumatology (ACR) Annual Meeting being held in Washington, D.C. The presentation will highlight new, pivotal Phase 3 study findings, including; Intravenous Golimumab Inhibits Radiographic Progression and...

2012-10-29 11:25:58

Be Joint Smart educates public about devastating disease affecting 87,000 Ohioans CLEVELAND, Oct. 29, 2012 /PRNewswire-USNewswire/ -- For the first-time ever, the National Psoriasis Foundation and the Arthritis Foundation will partner to educate Americans about psoriatic arthritis, a chronic autoimmune disease that affects roughly 87,000 Ohioans. To emphasize the importance of early diagnosis and treatment, the Psoriasis Foundation and Arthritis Foundation present the first psoriatic...

2012-10-25 07:31:45

MOUNTAIN VIEW, Calif., Oct. 25, 2012 /PRNewswire/ -- Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic class available to psoriatic arthritis (PsA) patients in need of additional therapy beyond standard of care. This represents a significant unmet need for alternative therapies for TNF inhibitor refractory patients. New analysis from Frost & Sullivan's (http://www.healthcare.frost.com) United States Market for Psoriatic Arthritis Pharmacotherapy research finds...

2012-10-18 07:25:44

MOUNTAIN VIEW, Calif., Oct. 18, 2012 /PRNewswire/ -- The availability of tumor necrosis factor (TNF) inhibitors has greatly improved the pharmacological management of rheumatoid arthritis (RA). Both patients and physicians are familiar with TNF inhibitors due to their long history; however, their many limitations such as high cost, potential side effects, and injection requirement have created a need for alternative therapies. This need, along with a potentially large patient pool,...

2012-10-12 07:22:33

Educational Conference on October 20 in Long Beach, California, Helps Young Adults with Arthritis, the Leading Cause of Disability in the United States LOS ANGELES, Oct 12, 2012 /PRNewswire-USNewswire/ -- The Arthritis Foundation is sponsoring the 3(rd) Annual PrimeTime symposium (formerly Arthritis in PrimeTime) on Saturday, October 20 at the Long Beach Renaissance Hotel in Long Beach, California. This premier educational and motivational event fosters active, productive and...

2012-10-11 11:23:44

ATLANTA, Oct. 11, 2012 /PRNewswire/ -- More Americans are walking, according to a new report from the Centers for Disease Control and Prevention (CDC). While the news is a step in the right direction, the report also highlights a need for many more Americans to join the movement. The Arthritis Foundation is joining a global effort on Oct. 12, World Arthritis Day, to encourage physical activity among people with arthritis. To view the multimedia assets associated with this release, please...

2012-10-09 15:25:06

VANCOUVER, Oct. 9, 2012 /PRNewswire/ - Augurex Life Sciences Corp. today announced that it has formed an exclusive license agreement with Quest Diagnostics, for the development of a clinical laboratory-developed testing service for the U.S. market, based on Augurex's rheumatoid arthritis (RA) 14-3-3h biomarker. Quest Diagnostics is the world's leading diagnostic testing company, and serves approximately half of the physicians and hospitals in the United States. Quest Diagnostics...

2012-10-09 15:24:36

Be Joint Smart educates public about devastating disease affecting 27,000 Oregonians PORTLAND, Ore., Oct. 9, 2012 /PRNewswire-USNewswire/ -- For the first-time ever, the Portland-based National Psoriasis Foundation and the Arthritis Foundation will partner to educate Americans about psoriatic arthritis, a chronic autoimmune disease that affects roughly 27,000 Oregonians. To emphasis the importance of early diagnosis and treatment, the Psoriasis Foundation and Arthritis Foundation...